Skip to main content
Premium Trial:

Request an Annual Quote

NimbleGen Files for IPO; Pricing Not Yet Determined

NEW YORK (GenomeWeb News) - NimbleGen has filed for an initial public offering with the Securities and Exchange Commission, the company said Friday.
 
The number and prices of shares have not yet been determined.
 
NimbleGen is a microarray developer that specializes in products and services for comparative genomic hybridization, chromatin immunoprecipitation arrays, comparative genome sequencing, and expression analysis.
 
J.P. Morgan will serve as bookrunner for the offering, Thomas Weisel Partners will be co-lead manager, and Leerink-Swan and Robert W. Baird are acting co-managers.
 
NimbleGen has signed several agreements to secure fundamental array IP over the last six months. Last October, the company licensed the rights to Affymetrix’s microarray patents, and in January it licensed rights to Oxford Gene Technology’s patents.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.